Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay N Cohn

Showing results (91-100 of 171) with videos related to

Pageof 18
Sort By:
Circulation. Heart Failure|March 14, 2014
Prognostic value of soluble ST2 in the Valsartan Heart Failure TrialInder S Anand, Thomas S Rector, Michael Kuskowski, et al.
Circulation. Heart Failure|June 28, 2014
Effect of fixed-dose combination of isosorbide dinitrate and hydralazine on all hospitalizations and on 30-day readmission rates in patients with heart failure: results from the African-American Heart Failure TrialInder S Anand, Sithu Win, Thomas S Rector, et al.
Journal of the American College of Cardiology|October 24, 2002
Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitorsAldo P Maggioni, Inder Anand, Sidney O Gottlieb, et al.
Circulation|August 27, 2003
Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure TrialJay N Cohn, Inder S Anand, Roberto Latini, et al.
European Journal of Heart Failure|January 8, 2013
Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFTInder S Anand, Thomas S Rector, Michael Kuskowski, et al.
Congestive Heart Failure (Greenwich, Conn.)|October 5, 2010
Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT)Javed Butler, Inder S Anand, Michael A Kuskowski, et al.
Circulation|October 7, 2009
Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failureInder S Anand, Kalkidan Bishu, Thomas S Rector, et al.
Circulation. Heart Failure|October 8, 2009
Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure TrialInder S Anand, Thomas S Rector, Michael Kuskowski, et al.
American Heart Journal|August 11, 2012
Underuse of cardiovascular preventive pharmacotherapy in patients presenting with ST-elevation myocardial infarctionMichael D Miedema, Jay N Cohn, Ross F Garberich, et al.
Journal of Cardiac Failure|May 10, 2005
Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure TrialGiuseppina Majani, Anna Giardini, Cristina Opasich, et al.
Pageof 18

Showing results (91-100 of 171) with videos related to

Sort By:
Pageof 18
Circulation. Heart Failure|March 14, 2014
Prognostic value of soluble ST2 in the Valsartan Heart Failure TrialInder S Anand, Thomas S Rector, Michael Kuskowski, et al.
Circulation. Heart Failure|June 28, 2014
Effect of fixed-dose combination of isosorbide dinitrate and hydralazine on all hospitalizations and on 30-day readmission rates in patients with heart failure: results from the African-American Heart Failure TrialInder S Anand, Sithu Win, Thomas S Rector, et al.
Journal of the American College of Cardiology|October 24, 2002
Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitorsAldo P Maggioni, Inder Anand, Sidney O Gottlieb, et al.
Circulation|August 27, 2003
Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure TrialJay N Cohn, Inder S Anand, Roberto Latini, et al.
European Journal of Heart Failure|January 8, 2013
Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFTInder S Anand, Thomas S Rector, Michael Kuskowski, et al.
Congestive Heart Failure (Greenwich, Conn.)|October 5, 2010
Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT)Javed Butler, Inder S Anand, Michael A Kuskowski, et al.
Circulation|October 7, 2009
Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failureInder S Anand, Kalkidan Bishu, Thomas S Rector, et al.
Circulation. Heart Failure|October 8, 2009
Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure TrialInder S Anand, Thomas S Rector, Michael Kuskowski, et al.
American Heart Journal|August 11, 2012
Underuse of cardiovascular preventive pharmacotherapy in patients presenting with ST-elevation myocardial infarctionMichael D Miedema, Jay N Cohn, Ross F Garberich, et al.
Journal of Cardiac Failure|May 10, 2005
Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure TrialGiuseppina Majani, Anna Giardini, Cristina Opasich, et al.
Pageof 18